Neuroprotection - STAIR-way to the future?

Cerebrovascular Diseases

Volumn 22, Issue SUPPL. 1, 2006, Pages 10-17

  Shuaib, Ashfaq ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acute ischaemic stroke; Neuroprotection; NXY 059; Preclinical development; Primate; Stroke Therapy Academic Industry Roundtable (STAIR)

Indexed keywords

CLOMETHIAZOLE; DISUFENTON SODIUM; FREE RADICAL; GLUTAMATE RECEPTOR ANTAGONIST; ION TRANSPORT AFFECTING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ACUTE DISEASE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DISABILITY; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVALUATION; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 33646572857     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092328     Document Type: Conference Paper

References (30)

1. World Health Organization: Statistical Information System. World Health Organization 2004.
2. Fisher M, for the Stroke Therapy Academic Industry Roundtable: Recommendations for advancing development of acute stroke therapies. Stroke Therapy Academic Industry Roundtable 3. Stroke 2003;34:1539-1546.
3. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-397.
4. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjö BK: Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999;19:778-787.
5. Marshall JW, Duffin KJ, Green AR, Ridley RM: NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001;32:190-198.
6. Marshall JWB, Cummings RM, Bowes LJ, Ridley RM, Green AR: Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 h after occlusion. Stroke 2003;34:2228-2233.
7. Sydserff SG, Borelli AR, Green AR, Cross AJ: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002;135:103-112.
8. Kidwell CS, Liebeskind DS, Starkman S, Saver JL: Trends in acute ischemic stroke trials through the 20th century. Stroke 2001;32:1349-1359.
9. Ovbiagele B, Kidwell CS, Starkman S, Saver JL: Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2003;3:9-20.
10. Lees KR, Zivin JA, Ashwood T, Davalos A, Davies SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW: NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600.
11. Dawson DA, Wadsworth G, Palmer AM: A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res 2001;892:344-350.
12. Muir KW, Lees KR: Clinical experiences with excitatory amino acid antagonists. Stroke 1995;26:503-513.
13. Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claesson L, Odergren T, Salazar-Grueso E: Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke 2002;33:122-128.
14. Sydserff SG, Cross AJ, Murray TK, Jones JA, Green AR: Clomethiazole is neuroprotective in models of global and focal cerebral ischemia when infused at doses producing clinically relevant plasma concentrations. Brain Res 2000;862:59-62.
15. Massieu L, Thedinga KH, McVey M, Fagg GE: A comparative analysis of the neuroprotective properties of competitive and uncompetitive N-methyl-D-aspartate receptor antagonists in vivo: implications for the process of excitotoxic degeneration and its therapy. Neuroscience 1993;55:883-892.
16. Green AR, Odergren T, Ashwood T: Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 2003;24:402-408.
17. NINDS rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
18. Brinker G, Franke C, Hoehn M, Uhlenkuken U, Hourihane JM: Thrombolysis of cerebral clot embolism in rat: effect of treatment delay. NeuroReport 1999;10:3269-3272.
19. Dewar D: Drug development for stroke: importance of protecting cerebral white matter. Eur J Pharmacol 1999;375:41-50.
20. Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM: NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 2001;909:46-50.
21. Ringelstein EB, Biniek R, Weiller C, Ammeling B, Nolte PN, Thron A: Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 1992;42:289-298.
22. Marshall JW, Ridley RM: Assessment of functional impairment following permanent middle cerebral artery occlusion in a non-human primate species. Neurodegeneration 1996;5:275-286.
23. Marshall JW, Cross AJ, Ridley RM: Functional benefit from clomethiazole treatment after focal cerebral ischaemia in non-human primate species. Exp Neurol 1999;156:121-129.
24. Stroke Therapy Academic Industry Roundtable (STAIR): Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-2758.
25. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson M, Norris J: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347-354.
26. Marshall JW, Ridley RM: Assessment of cognitive and motor deficits in a marmoset model of stroke. ILAR J 2003;44:153-160.
27. Siesjo BK, Agardh CD, Bengtsson F: Free radical and brain damage. Brain Metab Rev 1989;1:165-211.
28. Grotta J: Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 2002;33:306-307.
29. Robertson IH, Halligan PW, Marshall JC: Prospects for the rehabilitation of unilateral neglect; in Robertson IH, Marshall JC (eds): Unilateral Neglect: Clinical and Experimental studies. Hove, UK, Lawrence Erlbaum Associates Ltd, 1993.
30. Lees KR, Barer D, Ford GA, Hacke W, Kostulas V, Sharma AK, Odergren T, for the SA-NXY-0004 Investigators: Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003;34:482-487.